Ariceum Therapeutics creates systemic targeted radiotherapy (STR) agents that combine tumor‑specific ligands with alpha‑emitting isotopes, delivering potent, short‑range radiation while enabling real‑time PET or SPECT imaging. This integrated diagnostic‑therapeutic approach aims to improve precision, reduce off‑target toxicity, and expand treatment options for metastatic cancers such as small‑cell lung cancer and Merkel cell carcinoma.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OAPFounders
Product
Problem
Current cancer treatments often lack the ability to simultaneously visualize tumors and deliver highly localized radiation, leading to systemic side effects and limited efficacy for metastatic disease.
Solution
Ariceum Therapeutics develops systemic targeted radiotherapy (STR) agents that combine diagnostic imaging and therapeutic radiation in a single radiopharmaceutical. By conjugating tumor‑specific ligands to alpha‑emitting isotopes, the platform delivers potent, short‑range radiation directly to cancer cells while enabling real‑time PET or SPECT imaging to monitor distribution and response. The approach aims to improve treatment precision, reduce off‑target toxicity, and expand therapeutic options for hard‑to‑treat cancers such as small‑cell lung cancer and Merkel cell carcinoma. Clinical programs evaluate safety, biodistribution, and efficacy of these agents in early‑phase trials.
Target Audience
Primary customers are oncology clinicians and pharmaceutical partners developing targeted radiopharmaceutical therapies for metastatic and refractory cancers.
Features
- Alpha‑emitting radionuclides (e.g., ^225Ac) linked to tumor‑targeting molecules for high‑LET radiation delivery
- Integrated imaging capability using isotopic signatures for PET/SPECT visualization of drug uptake
- Modular ligand platform allowing adaptation to multiple tumor antigens
- Optimized pharmacokinetics to achieve systemic circulation with rapid tumor accumulation and clearance from healthy tissue
- Manufacturing process compliant with GMP for clinical‑grade radiopharmaceutical production